Company Filing History:
Years Active: 2023-2024
Title: Dianze Chen: Innovator in Biopharmaceuticals
Introduction
Dianze Chen is a prominent inventor based in Shanghai, China, known for his significant contributions to the field of biopharmaceuticals. With a total of three patents to his name, he has made remarkable advancements in the development of therapeutic antibodies.
Latest Patents
Dianze Chen's latest patents include innovative technologies that target CD24 and CD47. One of his patents, titled "Antibodies binding CD24, preparation and use thereof," discloses an antibody that specifically binds to CD24. This patent also includes a nucleic acid molecule encoding the antibody, an expression vector, and a method for treating diseases associated with CD24 signaling. Another notable patent is "Recombinant fusion proteins targeting CD47 and CD24, preparation and use thereof." This application provides a recombinant fusion protein that can bind to CD47, CD24, and FcR simultaneously, along with methods for producing the protein and treating diseases related to the overexpression of CD47 and/or CD24.
Career Highlights
Dianze Chen is currently employed at Immuneonco Biopharmaceuticals (Shanghai) Inc., where he continues to push the boundaries of biopharmaceutical research. His work focuses on developing novel therapeutic strategies that leverage the immune system to combat various diseases.
Collaborations
Dianze collaborates with esteemed colleagues, including Wenzhi Tian and Song Li, who contribute to his research endeavors and help advance the company's mission in biopharmaceutical innovation.
Conclusion
Dianze Chen's work exemplifies the spirit of innovation in the biopharmaceutical industry. His patents and ongoing research are paving the way for new treatments that could significantly impact patient care.